

# *WKS Assays, Inc.*

Horseradish Peroxidase  
Immunoassays

Patrick A. Williams

Ian M. Klink

Brandon D. Shaw

Chemical Engineering Senior Design Project

# Overview

- I. Purpose
- II. Immunoassay
- III. Market
- IV. Characteristics of Our Immunoassay
- V. Design Options
- VI. Fabrication
- VII. FDA Approval
- VIII. Financial Risk

# Objectives & Goals

- Produce a quality diagnostic test
- Provide leading immunoassays for bacterial detection
- Target rural hospital market initially
- **Make Money**

Purpose

Immunoassay

Market

Characteristics

Design Options

Fabrication

FDA Approval

Financial Risk



# Product

## Immunoassay Kit

- Analytical test
- Targets specific molecule
- Results obtained by signal generation

Purpose

Immunoassay

Market

Characteristics

Design Options

Fabrication


FDA Approval

Financial Risk

# Why *S. aureus* immunoassay?

## *Staphylococcus aureus*

- Major cause of hospital infections
- 8 common infections
- Can cause deadly complications
- Hospital Infections 4<sup>th</sup> leading cause of US deaths



[www.ulb.ac.be/sciences/biodic/ ImBacterie2.html](http://www.ulb.ac.be/sciences/biodic/ImBacterie2.html)

- Purpose
- Immunoassay
- Market
- Characteristics
- Design Options
- Fabrication
- FDA Approval
- Financial Risk

# Why *S. aureus* immunoassay?

## Common Conditions

Purpose

Immunoassay

Market

Characteristics

Design Options

Fabrication

FDA Approval

Financial Risk

Infection	Description
<i>Folliculitis</i>	inflammation of the follicles
<i>Boils</i>	painful, pus-filled inflammation of the skin and subcutaneous tissue
<i>Sties</i>	Inflammation of one or more sebaceous glands of an eyelid
<i>Impetigo</i>	a contagious skin infection
<i>Abscesses</i>	A localized collection of pus in part of the body, formed by tissue disintegration and surrounded by an inflamed area
<i>Staphylococcal pneumonia</i>	inflammation of the lungs
<i>Osteomyelitis</i>	onset after surgery
<i>Toxic shock syndrome</i>	acute infection associated with tampon use during menstruation

# *S. aureus* immunoassay

- Early detection yields better treatment
- Sanitation control
- Can be modeled and adapted to other immunoassays

Purpose

Immunoassay

Market

Characteristics


Design Options

Fabrication

FDA Approval

Financial Risk

# Immunoassay



# Components

## Antibody

- Immune system vesicle

Purpose

Immunoassay

Market

Characteristics

Design Options

Fabrication

FDA Approval

Financial Risk

## Antigen

- Molecule being detected

## Enzyme


- Oxidizing agent using in signal generation

## Substrate

- Signal generator in conjunction with enzyme

# Background


- **Antibody**
  - **Chains**
  - **Regions**
  - **Types**
    - **Polyclonal**
    - **Monoclonal**



- Purpose
- Immunoassay
- Market
- Characteristics
- Design Options
- Fabrication
- FDA Approval
- Financial Risk

# Background

- Which antibody for our assay?
  - Immunoglobulin G (IgG)
- Why IgG?
  - Widely available
  - Higher antigen affinity compared to other antibodies
- Structure of IgG



Purpose

Immunoassay

Market

Characteristics

Design Options


Fabrication

FDA Approval

Financial Risk

# Background

- Antigen — Protein A
  - Source - *Staphylococcus aureus*



Purpose

Immunoassay

Market

Characteristics

Design Options


Fabrication

FDA Approval

Financial Risk

# Background

- Immunoassays
  - Immunometric
  - Enzyme linked immunosorbent assay



Purpose

Immunoassay

Market

Characteristics

Design Options

Fabrication

FDA Approval

Financial Risk

# Background

## o Immunoassays

Purpose

Immunoassay

Market


Characteristics

Design Options

Fabrication

FDA Approval

Financial Risk



Enzyme Catalyzed Reaction to Produce Signal

# Immunoassay Operation

- Equilibrium test
- Approximately 3 hours
- Working Range
  - Pico-molar

*WKS Assays, Inc.*

# ○ Laboratory operation

Purpose

Immunoassay

Market


Characteristics

Design Options


Fabrication

FDA Approval

Financial Risk



Market



# Market

- Target market segment
  - Rural hospitals
- Why rural hospitals?
  - Untapped market
- Technology — Cost barrier
  - Automated throughput vs. manual
  - Prohibitive capital cost



Purpose

Immunoassay

Market

Characteristics

Design Options

Fabrication

FDA Approval

Financial Risk

# Market

## ○ Rural Hospital Infection Rates

Purpose

Immunoassay

Market

Characteristics

Design Options

Fabrication

FDA Approval

Financial Risk

- **300,000 total infections annually in rural hospitals**
- ***S. aureus* responsible for approximately 76,000 infections**
- **300,000 assays required to test all patients presenting symptoms**

# Market

- **Rural Hospital Trends**
- **Recent growth in rural population**
  - **6% increase in hospital discharges between 1995 & 2000**
  - **11% growth in rural population between 1990 & 2000**
- **Rural hospital discharges to increase**
  - **Discharges expected to increase 10% between 2005 & 2014**

Purpose

Immunoassay

Market

Characteristics

Design Options

Fabrication

FDA Approval

Financial Risk

# Market

- **Competition**
  - **Larger biotechnology companies**
  - **Remel, Sure-Vue, Murel**
- **Our Advantages**
  - **Quantitative Detection**
  - **Shorter waiting time**
  - **Does not require sample culturing**

Purpose

Immunoassay

Market

Characteristics


Design Options

Fabrication

FDA Approval

Financial Risk

# Immunoassay Characteristics



# Reagents & Components

- **What's in the box?**
  - Two 96 - well plates
  - HRP-IgG conjugate solution
  - Wash buffer
  - TMB Substrate solution
  - Stop Solution
  - Standard Antigen Solution
  - Standard Dose Response Curve



Purpose

Immunoassay

Market

Characteristics

Design Options


Fabrication

FDA Approval

Financial Risk

# Reagents & Components

- **96 well plate**
  - Standard for use with ELISA
  - Allows for multiple sample testing
  - Polystyrene



- **IgG-HRP conjugate solution**
  - Signal generation component of assay

Purpose

Immunoassay

Market

Characteristics

Design Options


Fabrication

FDA Approval

Financial Risk

# Reagents & Components

- Wash buffer
  - TRIS buffered saline with 0.1% Tween
- Hydrogen peroxide
  - Oxidizing agent
- TMB Substrate solution
  - 3,3',5,5'-tetramethylbenzidine
  - Produces strong signal
  - Lacks mutagenic qualities



Purpose

Immunoassay

Market

Characteristics

Design Options

Fabrication

FDA Approval

Financial Risk

# Reagents & Components

- Assay buffer
  - TRIS buffered saline with 1% BSA  
**(Bovine Serum Albumin)**
- Standard antigen solution
  - Protein A antigen solution
  - 4 concs. that span working range



Purpose

Immunoassay

Market

Characteristics

Design Options

Fabrication

FDA Approval

Financial Risk

# Reagents & Components

- Stop solution
  - 1M hydrochloric acid
- Standard dose response curve
  - Signal vs. antigen conc.
  - Conc. as low as 800 pg/mL

Purpose

Immunoassay

Market

Characteristics

Design Options

Fabrication

FDA Approval

Financial Risk



# HRP Kinetics

## Enzyme Reaction

- HRP undergoes three reactions to generate signal



Color is generated from oxidized substrate radical

Purpose

Immunoassay

Market

Characteristics

Design Options

Fabrication

FDA Approval

Financial Risk

# HRP Kinetics

- Stop solution will be added to the mix after 10 minutes.
- Spectrophotometer is used to measure the concentration of colored substrate in solution
- $\lambda=403\text{ nm}$

Purpose

Immunoassay

Market

Characteristics

Design Options


Fabrication

FDA Approval

Financial Risk

# Kinetic Analysis

- Antibody-antigen binding
  - Surface adsorption kinetics



- Three binding reactions of interest
  - Antibody to surface
  - Antigen to antibody
  - Labeled antibody to antigen-antibody surface complex

Purpose

Immunoassay

Market

Characteristics

Design Options


Fabrication

FDA Approval

Financial Risk

# Kinetic Analysis

- Evaluation of rate constants
  - How?
- BIACore s51



Purpose

Immunoassay

Market

Characteristics

Design Options

Fabrication


FDA Approval

Financial Risk

# Kinetic Analysis

## Plate Antibody Binding

- Binding reaction of antibody to surface



- First order surface adsorption kinetics
- Adsorption and Desorption reactions considered

$$\text{Adsorption} = r_{AD} = k_3 C_{Ab} C_{v,S}$$

$$\text{Desorption} = r_{DES} = k_{-3} C_{SAb}$$

$$\text{Equilibrium} = K_3 = \frac{k_3}{k_{-3}}$$

$$\text{Netrate} = r_{AD} - r_{DES} = k_3 C_{Ab} C_{v,S} - k_{-3} C_{SAb}$$

Purpose

Immunoassay

Market

Characteristics

Design Options


Fabrication

FDA Approval

Financial Risk

# Kinetic Analysis

## ○ Binding of antigen to antibody



$$\text{Adsorption} = r_{AD} = k_2 C_{v,SAb} C_{Ag}$$

$$\text{Desorption} = r_{DES} = k_{-2} C_{SAb-Ag}$$

$$\text{Equilibrium} = K_2 = \frac{k_2}{k_{-2}}$$

$$\text{Net rate} = r_{AD} - r_{DES} = k_2 C_{v,SAb} C_{Ag} - k_{-2} C_{SAb-Ag}$$

Purpose

Immunoassay

Market

Characteristics

Design Options


Fabrication

FDA Approval

Financial Risk

# Kinetic Analysis

## ○ Surface complex binding



Purpose

Immunoassay

Market

Characteristics

Design Options

Fabrication

FDA Approval

Financial Risk

$$Adsorption = k_5 C_{HRP-Ab} C_{v,SAb-Ag}$$

$$Desorption = k_{-5} C_{SAb-Ag-Ab-HRP}$$

$$Equilibrium = \frac{k_5}{k_{-5}} = K_5$$

$$Netrate = k_5 \left[ C_{HRP-Ab} C_{v,SAb=Ag} - \frac{C_{SAb-Ag=Ab-HRP}}{K_5} \right]$$

# Kinetic Analysis

## Equilibrium interaction model

$$r_{SAb-Ag} = k_2 \left[ C_{Ag} C_{v,SAb} - \frac{C_{SAb-Ag}}{K_2} \right]$$

$$r = k_1 C_{HRP-Ab} C_{v,SAb-Ag} - \frac{C_{SAb-Ag-Ab-HRP}}{K_1}$$

$$r_{bind.} = k_1 \left[ C_{SAb} C_{HRP-Ab-Ag} - \frac{C_{SAb-Ag-Ab-HRP}}{K_1} \right]$$

Purpose

Immunoassay

Market

Characteristics

Design Options

Fabrication

FDA Approval

Financial Risk

# Kinetic Analysis

- Assume Adsorption & Desorption rates are equal to zero
- Solve for unknown concentrations

$$C_{SAb-Ag} = K_1 (C_{Ag} C_{v,SAb})$$

$$C_{Ag} = C_{Ag,0} - C_{SAb-Ag} - C_{SAb-Ag-Ab-HRP} - C_{HRP-Ab-Ag}$$

$$C_{SAb-Ag} = K_1 [(C_{Ag,0} - C_{SAb-Ag} - C_{SAb-Ag-Ab-HRP} - C_{HRP-Ab-Ag}) C_{v,SAb}]$$

- Initial antigen concentration is known
- Initial surface antibody conc. is known

Purpose

Immunoassay

Market

Characteristics

Design Options

Fabrication

FDA Approval

Financial Risk

# Kinetic Analysis

- System of 3 equations
  - Solved using Polymath™
- Conc. of surface antibody-antigen complex critical variable
- Strength of signal is defined by this concentration

Purpose

Immunoassay

Market

Characteristics

Design Options


Fabrication

FDA Approval

Financial Risk

# Kinetic Analysis

- Dose response curve
  - Indicates antigen concentration
  - Curve asymptotes as surface antibody concentration is approached



Purpose

Immunoassay

Market

Characteristics

Design Options

Fabrication

FDA Approval

Financial Risk

# Sensitivity

- Assay sensitivity
  - How low can we go?
- Determined by surface complex concentration
  - Minimum complex conc.= $1.8 \times 10^{-15}$  mol/cm<sup>2</sup>

Purpose

Immunoassay

Market

Characteristics

Design Options

Fabrication

FDA Approval

Financial Risk

# Sensitivity

- Signal strength increases with surface antibody concentration
- Optimize cost of surface antibody using this plot
- Use minimum amount of surface antibody that can generate signal

Purpose

Immunoassay

Market

Characteristics

Design Options

Fabrication

FDA Approval

Financial Risk

# Sensitivity

## Purpose

### Immunoassay

## Market


## Characteristics

## Design Options

## Fabrication

FDA Approval

Financial Risk



# Sensitivity

- Dose response curve is only used in linear range
- Linear range= 800 pg/mL – 4000 pg/mL

Purpose

Immunoassay

Market

Characteristics


Design Options

Fabrication

FDA Approval

Financial Risk

# Design Options




# Evaluated Processes

## Horseradish Peroxidase (HRP) Extraction

- 2 Differential Extractors
- Biphasic Salt Solution
  - Polyethylene Glycol (PEG) & KPO<sub>4</sub>
- Reagent Cost  $\approx \$20,000$
- FCI  $\approx \$150,000$

Amount: 1.24kg  
Activity: 117U/mL



Modeled using  
SuperPro Designer 4.7

Purpose

Immunoassay

Market

Characteristics

Design Options

Fabrication

FDA Approval

Financial Risk

# Evaluated Processes

- Cost Comparison of Produced and Purchased HRP
- Purchase HRP
  - Annual requirement: 5 g/yr
  - Cost: \$15,000/yr
- Produce HRP
  - Approximate Labor cost: \$35,000/yr

Purpose

Immunoassay

Market

Characteristics

Design Options

Fabrication

FDA Approval

Financial Risk

# Evaluated Processes

- ## HRP Extraction *continued*
- Decided not to produce
  - Purchase HRP
    - Lyophilized
    - Small amounts needed
    - Efficient for small company
    - \$266 per 100 mg (Sigma)

Purpose

Immunoassay

Market

Characteristics


Design Options

Fabrication

FDA Approval

Financial Risk


# Fabrication



# Plate Preparation

## Polystyrene Plate Steps

1. Fill wells with IgG coating solution
2. Incubate for 18 hours
3. Remove coating solution. Wash.
4. Fill wells with 2<sup>nd</sup> coating solution
5. Incubate for 30 minutes.
6. Remove coating solution. Wash, and dry for 24 hours.



Purpose

Immunoassay

Market

Characteristics

Design Options

Fabrication


FDA Approval

Financial Risk


# Manufacturing

## Equipment


- 3 major pieces
  - Sterilization
  - Bottling
  - Labeling



STS Series



KFVG x212



HEA 105

Purpose

Immunoassay

Market

Characteristics

Design Options

Fabrication

FDA Approval

Financial Risk

# Manufacturing

## Gantt Chart: Components

Purpose

Immunoassay

Market

Characteristics

Design Options

Fabrication

FDA Approval

Financial Risk

ID	Task Name	Duration	Daily Operation									
			8	9	10	11	12	1	2	3	4	5
1	Assay Solution - Sterilization	0.5h			█							
2	Standard Solution - Sterilization	0.5h	█	█								
3	Wash Buffer - Sterilization	0.5h	█									
4	Conjugated HRP - Sterilization	0.5h		█	█							
5	Substrate (TMB) - Sterilization	0.5h			█	█						
6	Stop Solution - Sterilization	0.5h				█	█					
7	Assay Solution - Filling	0.5h			█	█						
8	Standard Solution - Filling	0.5h			█	█						
9	Wash Buffer - Filling	0.5h	█	█								
10	Conjugated HRP - Filling	0.5h			█	█						
11	Substrate (TMB) - Filling	0.5h			█	█						
12	Stop Solution - Filling	0.5h			█	█						
13	Assay Solution - Labeling	1.0h			█	█						
14	Standard Solution - Labeling	1.0h			█	█						
15	Wash Buffer - Labeling	1.0h	█	█								
16	Conjugated HRP - Labeling	1.0h			█	█						
17	Substrate (TMB) - Labeling	1.0h				█	█					
18	Stop Solution - Labeling	1.0h					█	█				

Raw Materials

Operating Labor

Packaging

00

69

70

# Packaging

## Shipping Box

- 6"x6"x4" Indestructo Mailing

## Gray Convolved Foam

- 8"x6"x2"

## Yearly Packaging Costs

\$24,370



Purpose

Immunoassay

Market

Characteristics

Design Options

Fabrication

FDA Approval

Financial Risk

# Quality Control

- Random quality audits
  - 2.5% of each assay batch
- Verification of standard working range
  - Error greater than 5% → audit
  - 2.5% of testing assays → discard

Purpose

Immunoassay

Market

Characteristics

Design Options


Fabrication

FDA Approval

Financial Risk

# Quality Control

- Apparatus
  - Xiril™ X100 combination liquid handler and plate reader
  - Higher test throughput
  - Less chance of human error



Purpose

Immunoassay

Market

Characteristics


Design Options

Fabrication

FDA Approval

Financial Risk

FDA Approval



# Why FDA Approval

## Food & Drug Administration

- Government organization

- Protects Consumers


- Promotes Public Health

- Regulates Medical Devices

- Approval

- Require for US sales

- Quality product endorsement



Purpose

Immunoassay

Market

Characteristics


Design Options

Fabrication

FDA Approval

Financial Risk

# FDA Testing Phases



Purpose

Immunoassay

Market

Characteristics

Design Options

Fabrication

FDA Approval

Financial Risk

# FDA Testing Decisions

- How much pre FDA testing should we do?
  - Should we perform many tests in the same phase, or just a few?
  - After what phase should we enter the FDA approval process?
- To answer these questions we developed a novel model of the FDA approval process.

Purpose

Immunoassay

Market


Characteristics

Design Options

Fabrication

FDA Approval


Financial Risk



Phase 3: Chemical Inhibition Testing

Phase 4: Quality Control

# FDA Approval Outline



Purpose

Immunoassay

Market

Characteristics


Design Options

Fabrication

FDA Approval

Financial Risk

# Financial Risk



# Stochastic Modeling

## ○ Evaluated Design Variables

Purpose

Immunoassay

Market

Characteristics

Design Options

Fabrication

FDA Approval

Financial Risk

Option	Number of Tests	FDA
1	Phase 1 & 2 1000 Phase 3 & 4 500	Phase 4
2	Phase 1 & 2 1000 Phase 3 & 4 500	Phase 3
3	Phase 1 & 2 500 Phase 3 & 4 250	Phase 4
4	Phase 1 & 2 500 Phase 3 & 4 250	Phase 3

# Stochastic Modeling

- Evaluate all possible pathways in the FDA model for each design variable to determine:
  - Cost
  - Time
  - NPW

Purpose

Immunoassay

Market

Characteristics

Design Options

Fabrication

FDA Approval

Financial Risk

# Stochastic Modeling

Purpose

Immunoassay

Market


Characteristics

Design Options

Fabrication

FDA Approval

Financial Risk



# Stochastic Modeling

## ○ Risk Assessment

Purpose

Immunoassay

Market


Characteristics

Design Options

Fabrication

FDA Approval

Financial Risk



# Stochastic Modeling

- Option 1 gave the best results
  - Thorough testing through all phases reduces the uncertainty in the FDA approval process
- Estimated testing cost: \$1.8 Million
  - Pre FDA Testing: \$1 Million
  - FDA Testing: \$800,000
- Estimated time: 1.7 years

Purpose

Immunoassay

Market

Characteristics

Design Options

Fabrication

FDA Approval

Financial Risk

# Breakdown

- **Estimated Annual Sales**
  - 250,000 Immunoassay Kits
  - \$125 per kit
  - **Total Sales: \$31 Million**
- **Total Product Cost**
  - \$30 million
- **Total Capital Investment**
  - \$5.8 Million
- **Estimated NPW**
  - -\$2 Million



Purpose

Immunoassay

Market

Characteristics

Design Options

Fabrication

FDA Approval

Financial Risk

# Questions

Purpose

Immunoassay

Market

Characteristics

Design Options

Fabrication

FDA Approval

Financial Risk

???